1. Home
  2. TLS vs ALT Comparison

TLS vs ALT Comparison

Compare TLS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$5.76

Market Cap

463.8M

Sector

Technology

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$5.22

Market Cap

501.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLS
ALT
Founded
1969
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.8M
501.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
TLS
ALT
Price
$5.76
$5.22
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$7.75
$16.33
AVG Volume (30 Days)
1.1M
3.3M
Earning Date
11-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$144,400,000.00
$20,000.00
Revenue This Year
$47.80
N/A
Revenue Next Year
$26.19
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.44
N/A
52 Week Low
$1.83
$2.90
52 Week High
$8.36
$10.88

Technical Indicators

Market Signals
Indicator
TLS
ALT
Relative Strength Index (RSI) 41.42 74.79
Support Level $5.68 $4.40
Resistance Level $5.99 $4.75
Average True Range (ATR) 0.55 0.29
MACD -0.04 0.10
Stochastic Oscillator 13.26 92.19

Price Performance

Historical Comparison
TLS
ALT

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: